Invivyd, Inc. (NASDAQ:IVVD) Sees Significant Increase in Short Interest

Invivyd, Inc. (NASDAQ:IVVD) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 3,980,000 shares, a growth of 8.4% from the December 31st total of 3,670,000 shares. Based on an average daily trading volume, of 958,500 shares, the days-to-cover ratio is currently 4.2 days. Currently, 5.3% of the shares of the stock are short sold.

Insider Transactions at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 86,545 shares of Invivyd stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $0.48, for a total transaction of $41,541.60. Following the completion of the transaction, the director now owns 3,170,231 shares in the company, valued at approximately $1,521,710.88. The trade was a 2.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 816,466 shares of company stock valued at $423,214 in the last 90 days. 17.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of IVVD. State Street Corp lifted its holdings in shares of Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after acquiring an additional 35,904 shares in the last quarter. Marshall Wace LLP grew its position in shares of Invivyd by 4.2% during the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after buying an additional 31,992 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Invivyd in the second quarter worth $421,000. Cubist Systematic Strategies LLC raised its holdings in shares of Invivyd by 66.1% during the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after buying an additional 53,499 shares during the last quarter. Finally, Barclays PLC boosted its position in Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after acquiring an additional 75,780 shares during the period. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Invivyd Stock Up 196.3 %

Shares of NASDAQ:IVVD opened at $1.06 on Tuesday. The company has a market cap of $126.80 million, a P/E ratio of -0.54 and a beta of 0.61. The business has a fifty day simple moving average of $0.50 and a 200-day simple moving average of $0.82. Invivyd has a 52 week low of $0.35 and a 52 week high of $5.10.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. HC Wainwright cut their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. D. Boral Capital restated a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a research report on Monday. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Morgan Stanley reduced their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.